Arrowhead Pharmaceuticals Inc (ARWR)
22.61
+0.08
(+0.36%)
USD |
NASDAQ |
Apr 18, 16:00
22.63
+0.02
(+0.09%)
After-Hours: 20:00
Arrowhead Pharmaceuticals Enterprise Value: 2.594B for April 18, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 18, 2024 | 2.594B |
| April 17, 2024 | 2.584B |
| April 16, 2024 | 2.726B |
| April 15, 2024 | 2.768B |
| April 12, 2024 | 2.853B |
| April 11, 2024 | 2.975B |
| April 10, 2024 | 2.939B |
| April 09, 2024 | 3.045B |
| April 08, 2024 | 2.977B |
| April 05, 2024 | 2.987B |
| April 04, 2024 | 3.028B |
| April 03, 2024 | 3.074B |
| April 02, 2024 | 3.038B |
| April 01, 2024 | 3.292B |
| March 28, 2024 | 3.336B |
| March 27, 2024 | 3.349B |
| March 26, 2024 | 3.242B |
| March 25, 2024 | 3.249B |
| March 22, 2024 | 3.164B |
| March 21, 2024 | 3.291B |
| March 20, 2024 | 3.282B |
| March 19, 2024 | 3.234B |
| March 18, 2024 | 3.279B |
| March 15, 2024 | 3.297B |
| March 14, 2024 | 3.190B |
| Date | Value |
|---|---|
| March 13, 2024 | 3.335B |
| March 12, 2024 | 3.330B |
| March 11, 2024 | 3.436B |
| March 08, 2024 | 3.937B |
| March 07, 2024 | 3.906B |
| March 06, 2024 | 4.179B |
| March 05, 2024 | 4.015B |
| March 04, 2024 | 4.143B |
| March 01, 2024 | 4.263B |
| February 29, 2024 | 3.770B |
| February 28, 2024 | 4.006B |
| February 27, 2024 | 3.654B |
| February 26, 2024 | 3.571B |
| February 23, 2024 | 3.708B |
| February 22, 2024 | 3.535B |
| February 21, 2024 | 3.408B |
| February 20, 2024 | 3.413B |
| February 16, 2024 | 3.446B |
| February 15, 2024 | 3.457B |
| February 14, 2024 | 3.464B |
| February 13, 2024 | 3.500B |
| February 12, 2024 | 3.790B |
| February 09, 2024 | 3.827B |
| February 08, 2024 | 3.615B |
| February 07, 2024 | 3.714B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.431B
Minimum
May 01 2019
9.085B
Maximum
Feb 05 2021
4.256B
Average
3.650B
Median
Enterprise Value Benchmarks
| Madrigal Pharmaceuticals Inc | 3.910B |
| Viking Therapeutics Inc | 6.143B |
| Akero Therapeutics Inc | 890.45M |
| 89bio Inc | 292.47M |
| Sagimet Biosciences Inc | 32.44M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -132.86M |
| Revenue (Quarterly) | 3.551M |
| Total Expenses (Quarterly) | 140.10M |
| EPS Diluted (Quarterly) | -1.24 |
| Profit Margin (Quarterly) | -3.74K% |
| Earnings Yield | -12.25% |
| Normalized Earnings Yield | -12.25 |